Drugs / Buprenorphine
Buprenorphine
also known as
Suboxone · BUP · Buprenorphine/Naloxone · Sublocade · BTDS · buprenorphine hydrochloride · CAM2038 · Probuphine · +37 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | SUBLOCADE | — | 2025-02-21 | fda.gov ↗ |
| Label expansion | US (FDA) | BUTRANS | — | 2017-10-13 | fda.gov ↗ |
| Approved | EU (EMA) | Suboxone | — | 2006-09-26 | europa.eu ↗ |
| Approved | US (FDA) | BUPRENEX | — | 1981-12-29 | fda.gov ↗ |
Trials 307 · started per year
today
US approved 1981
EU approved 2006
3
2
1
3
10
3
4
4
8
5
4
3
4
4
7
12
9
11
9
13
10
10
14
19
12
5
12
7
10
10
12
9
10
8
11
6
8
10
1981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06726200 | Feb 2026 → Jan 2029 expected | substance-related disorder | Rachel R. Luba | Recruiting | No outcome recorded |
| Phase 0 | NCT03766893 | Sep → Dec 2018 | opiate dependence | Lifespan | Completed | No outcome recorded |
| Phase 0 | NCT03489161 | Aug 2018 | opiate dependence, substance withdrawal syndrome | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 0 | NCT01860287 | Sep 2013 → Jan 2017 | — | University of Chicago | Completed | No outcome recorded |
| Phase 143 trials | ||||||
| Phase 1 | NCT06086275 | Jun 2024 → Oct 2025 | substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04122755 | Sep 2019 → May 2021 | opiate dependence | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03996694 | Jul → Oct 2019 | respiratory underresponsiveness to hypoxia and hypercapnia | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 1 | NCT03975010 | May 2019 → Mar 2020 | chronic pain syndrome | Mundipharma (China) Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03747341 | Mar 2018 → Jan 2019 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03715634 | Sep 2017 → Jun 2018 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02666001 | Jan → Jun 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02372591 | Aug 2015 → Jun 2017 | chronic pain syndrome, opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02477267 | Jun → Jul 2015 | opiate dependence | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT02431624 | Mar → May 2015 | — | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 1 | NCT02160067 | May → Aug 2014 | — | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 1 | NCT01642030 | Aug 2013 → Jul 2017 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01311570 | Oct 2012 → Feb 2013 | depressive disorder | Shalvata Mental Health Center | Unknown | No outcome recorded |
| Phase 1 | NCT02198235 | Oct 2012 → Jan 2014 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 1 | NCT01671410 | Aug 2012 → Sep 2016 | neonatal abstinence syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT03002961 | Jul 2012 → Feb 2013 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01999114 | Mar → Oct 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT01396005 | Sep → Dec 2011 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01366001 | Aug 2011 → Feb 2012 | cocaine abuse | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01275599 | Jan → Apr 2011 | chronic hepatitis C virus infection, opiate dependence | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02765867 | Nov 2010 → May 2011 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01643759 | Jul 2009 → Mar 2010 | osteoarthritis | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00733720 | Aug → Dec 2008 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00877591 | Apr 2008 → Apr 2013 | HIV infectious disease, opiate dependence | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00469404 | May → Nov 2007 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00469053 | May → Nov 2007 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00387777 | Oct → Dec 2006 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00388219 | Oct → Nov 2006 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00347815 | Jun → Aug 2006 | — | Danish University of Pharmaceutical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT03785613 | Nov 2005 → Mar 2006 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00886002 | Nov 2004 → Jan 2005 | — | Janssen-Cilag A.G., Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01148537 | Jul → Dec 2004 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT03770234 | Apr → May 2004 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00521248 | Apr 2004 → Jan 2010 | neonatal abstinence syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT01259115 | Oct 2002 → Jun 2003 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT00015288 | Nov 1996 → ? | heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00015041 | Nov 1996 → Jun 1998 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00000355 | Nov 1994 → Jan 1996 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00000224 | Feb 1993 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00000222 | Jul 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00000221 | Apr 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00000219 | Dec 1991 → Jul 2001 | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 1 | NCT00000220 | Jun 1991 → Jul 2001 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT07430345 | May → Dec 2026 expected | — | The Cooper Health System | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06442566 | Aug 2024 → Mar 2028 expected | chronic pain syndrome, substance withdrawal syndrome | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03861338 | Mar 2019 → Feb 2020 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03580902 | Jan 2019 → Nov 2021 | opiate dependence | CBT4CBT, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03608696 | Aug 2018 → Jul 2019 | neonatal abstinence syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT02181231 | Jun 2016 → Apr 2018 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT02360007 | Jan 2015 → Jun 2016 | opiate dependence | University of Vermont Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02263248 | Dec 2014 → Jan 2017 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 1/2 | NCT02249026 | Oct 2014 → Jun 2016 | neonatal abstinence syndrome, toxic or drug-related embryofetopathy | Gauda, Estelle B., M.D. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01136356 | Jul 2010 → Mar 2012 | opiate dependence, opioid abuse | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00947466 | Feb 2010 → Nov 2012 | chemotherapy-induced oral mucositis | Mundipharma Research Limited | Terminated | No outcome recorded |
| Phase 1/2 | NCT00634803 | Sep 2009 → May 2015 | chronic pain syndrome, opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT00367302 | Aug 2006 → Jan 2008 | opiate dependence | National Development and Research Institutes, Inc. | Completed | No outcome recorded |
| Phase 279 trials | ||||||
| Phase 2 | NCT05339256 | Jun → Dec 2026 expected | substance-related disorder | New York State Psychiatric Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06441604 | Oct 2025 → Jun 2026 overdue | substance-related disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04737603 | Jul 2025 | opiate dependence | University of California, Davis | Withdrawn | No outcome recorded |
| Phase 2 | NCT06379984 | May 2025 → Dec 2026 expected | substance-related disorder | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT05778591 | May 2024 → Dec 2026 expected | schizophrenia | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT05262270 | Apr 2023 → Jun 2025 | substance-related disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05283304 | Mar → Oct 2023 | methamphetamine dependence | Madhukar H. Trivedi, MD | Terminated | No outcome recorded |
| Phase 2 | NCT04480554 | Jan 2023 → Jun 2025 | HIV infectious disease, opiate dependence | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT04454411 | Aug 2022 → Aug 2024 | opiate dependence | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT03744663 | Jun → Dec 2022 | substance-related disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT05991622 | Apr 2022 → Aug 2025 | HIV infectious disease, opiate dependence | Rhode Island Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT04752384 | Jul 2021 → Apr 2024 | head and neck squamous cell carcinoma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT04464980 | Jun 2021 → Dec 2026 expected | substance-related disorder | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04571619 | Jan 2021 → Dec 2023 | chronic pain syndrome, end stage renal failure, opiate dependence | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT04352166 | Dec 2020 → Jun 2025 | opiate dependence | Frances R Levin | Suspended | No outcome recorded |
| Phase 2 | NCT03492099 | Aug 2018 → Sep 2019 | sickle cell disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT03291847 | Jun 2018 → Dec 2022 | neonatal abstinence syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT03420313 | Mar 2018 → Jul 2021 | opiate dependence | University of Vermont | Unknown | No outcome recorded |
| Phase 2 | NCT03256487 | Sep 2017 → Feb 2018 | — | Alameda Health System | Unknown | No outcome recorded |
| Phase 2 | NCT03156907 | Sep 2017 → Dec 2024 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT03254459 | Sep → Nov 2017 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT02611752 | Oct 2015 → Apr 2016 | opiate dependence | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02710526 | Feb 2015 → May 2017 | chronic pain syndrome, opiate dependence | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02176291 | Aug 2014 → Apr 2017 | major depressive disorder | Jordan F. Karp | Completed | No outcome recorded |
| Phase 2 | NCT02044094 | Nov 2013 → Jul 2014 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01871285 | Jun 2013 → Jul 2014 | — | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01708707 | Dec 2012 → Oct 2017 | neonatal abstinence syndrome | Pediatrix | Completed | No outcome recorded |
| Phase 2 | NCT01666119 | Aug 2012 → Jan 2013 | opiate dependence | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01582347 | Mar → Nov 2012 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01500200 | Dec 2011 → Mar 2013 | major depressive disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01071538 | May 2010 → May 2012 | depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00941304 | Aug → Nov 2009 | dental pulp disorder | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT00612287 | Apr → May 2009 | chronic pain syndrome | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 2 | NCT00637000 | Mar → Sep 2008 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00640835 | Feb → Oct 2008 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00460239 | Jan 2007 → Jul 2009 | substance-related disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00403234 | Nov 2006 → Apr 2007 | — | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 2 | NCT00719095 | Apr 2006 → Mar 2010 | opiate dependence | University of Vermont Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01967641 | Nov 2005 → Jun 2011 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT01075971 | Sep → Nov 2005 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00182572 | Jul 2005 → ? | opiate dependence | National Development and Research Institutes, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00398008 | Oct 2004 → Dec 2006 | HIV infectious disease, opiate dependence | Yale University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00149539 | Jun 2004 → Jan 2006 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| Phase 2 | NCT00218101 | May 2004 → Mar 2005 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00383045 | Apr 2003 → Aug 2007 | opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00000334 | Dec 2002 → Nov 2004 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000331 | Dec 2002 | heroin dependence | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 2 | NCT00000240 | Apr 1999 → ? | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000328 | Jul → Aug 1997 | heroin dependence | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 2 | NCT00000237 | May 1997 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00315835 | Oct 1996 → Nov 1997 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 2 | NCT00000341 | Aug 1996 → Aug 2000 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000319 | Jun 1996 → Jan 2005 | opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00344812 | Jan 1996 → Jun 1998 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00000298 | Aug 1995 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000273 | Aug 1995 → Nov 2005 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00000230 | Jan 1995 → ? | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000318 | Dec 1994 → Mar 2004 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000226 | Nov 1994 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000227 | Aug 1994 → ? | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000223 | Jun 1993 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000233 | May 1993 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000225 | Dec 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000209 | Nov 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000357 | Jun 1992 → Aug 1993 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000232 | Mar 1992 → ? | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000208 | Feb 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000231 | Feb 1992 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000214 | Jan 1992 → Jan 1993 | cocaine abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00000206 | Apr 1991 → Aug 2005 | substance-related disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00000210 | Sep 1989 → Feb 1996 | cocaine dependence, heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000211 | Sep 1989 → Feb 1996 | cocaine abuse, heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000203 | Aug 1988 → May 2006 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00000202 | Aug 1988 → May 2006 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00000204 | Aug 1988 → May 2006 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00000234 | — | opiate dependence | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000236 | — | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000235 | — | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000239 | — | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT06316830 | Jan 2025 → Aug 2027 expected | substance-related disorder | Rhode Island Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05011266 | Apr 2023 → Jan 2027 expected | opiate dependence | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04991974 | Sep 2021 → Jan 2026 | opiate dependence | Friends Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04408313 | Oct 2020 → May 2026 overdue | opiate dependence | Friends Research Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03113409 | Jun 2017 → Dec 2020 | opiate dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2/3 | NCT01561079 | Feb 2012 → Jun 2016 | neonatal abstinence syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT01402492 | Sep 2011 → Jan 2013 | cocaine dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2/3 | NCT01082679 | Jun 2009 → Mar 2011 | opiate dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 376 trials | ||||||
| Phase 3 | NCT06306443 | Jun 2025 → Jan 2029 expected | substance-related disorder | Friends Research Institute, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07524738 | Jun 2025 → Jul 2026 overdue | substance-related disorder | Friends Research Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06494904 | Dec 2024 → Sep 2027 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
| Phase 3 | NCT05790252 | Nov 2023 → Jul 2026 overdue | pregnancy disorder, substance-related disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05589181 | Apr 2023 → Sep 2026 expected | substance-related disorder | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 3 | NCT05427981 | Oct 2022 → Jan 2024 | major depressive disorder | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT03616236 | Jul 2022 → Aug 2026 | substance-related disorder | Friends Research Institute, Inc. | Suspended | No outcome recorded |
| Phase 3 | NCT03646058 | Oct 2021 → Oct 2026 expected | major depressive disorder | Nîmes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04523792 | Jan → Dec 2021 | opiate dependence | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 3 | NCT04455802 | Oct 2020 → May 2021 | neonatal abstinence syndrome | Women and Infants Hospital of Rhode Island | Withdrawn | No outcome recorded |
| Phase 3 | NCT03678792 | Nov 2019 → Sep 2020 | opiate dependence, substance withdrawal syndrome | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 3 | NCT05164549 | Aug 2019 → Apr 2022 | — | King's College London | Completed | No outcome recorded |
| Phase 3 | NCT03967327 | Apr 2019 → Dec 2020 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03818399 | Jan 2019 → Feb 2021 | substance-related disorder | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 3 | NCT03711318 | Nov 2018 → Dec 2021 | heroin dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 3 | NCT03610048 | Aug 2018 → May 2020 | major depressive disorder | Alkermes, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03232346 | Aug 2017 → Jun 2021 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT03188185 | Jun 2017 → Feb 2020 | major depressive disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02891798 | Oct 2016 → Jul 2021 | — | Brian Williams | Completed | No outcome recorded |
| Phase 3 | NCT02946073 | Sep 2016 → May 2018 | chronic pain syndrome | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02696096 | Aug 2016 → Feb 2020 | opiate dependence | Butler Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02634788 | Jan → Jun 2016 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 3 | NCT02651584 | Dec 2015 → Oct 2016 | opiate dependence | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02672111 | Nov 2015 → May 2017 | substance-related disorder | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02537574 | Aug 2015 → Oct 2016 | substance-related disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02187198 | Mar 2015 → Feb 2022 | opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT02310581 | Feb → Mar 2015 | — | INSYS Therapeutics Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01755546 | Dec 2012 → Oct 2014 | neuropathy, painful, osteoarthritis | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT01675167 | Sep 2012 → Jun 2014 | — | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT01633944 | Aug 2012 → Dec 2013 | — | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT01431742 | Jul 2012 → Jul 2013 | — | BioDelivery Sciences International | Withdrawn | No outcome recorded |
| Phase 3 | NCT01324544 | Nov 2011 → Aug 2014 | — | Purdue Pharma LP | Withdrawn | No outcome recorded |
| Phase 3 | NCT01452789 | Nov 2011 → Jun 2016 | neonatal abstinence syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 3 | NCT01407575 | Sep 2011 → Aug 2013 | major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 3 | NCT01324570 | Jul 2011 → May 2016 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01298765 | Mar 2011 → Aug 2012 | neuropathy, painful, osteoarthritis | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT01262261 | Nov 2010 → Nov 2011 | opiate dependence | Titan Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01256450 | Nov 2010 → Jul 2011 | — | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT01114308 | Apr 2010 → May 2011 | opiate dependence | Titan Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01760473 | May 2009 → Dec 2014 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00574067 | Sep 2008 → Mar 2013 | heroin dependence | Friends Research Institute, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00772785 | Sep 2008 → Feb 2009 | opiate dependence | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00768482 | Sep → Dec 2008 | opiate dependence | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00630201 | Oct 2007 → Feb 2009 | opiate dependence | Titan Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00710385 | Sep 2007 → Aug 2008 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00531427 | Sep 2007 → Apr 2009 | chronic pain syndrome, osteoarthritis, knee | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00490919 | Jun 2007 → Jul 2008 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00346047 | May 2006 → Jul 2007 | — | Mundipharma K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00345787 | May 2006 → Aug 2007 | osteoarthritis | Mundipharma K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00271219 | Jul 2005 → Aug 2009 | opiate dependence, pregnancy disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT01125917 | Jun 2004 → Sep 2005 | — | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT01135524 | Apr 2004 → Aug 2005 | osteoarthritis | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00312221 | Apr 2004 → Jul 2005 | osteoarthritis | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00313014 | Feb 2004 → Sep 2005 | — | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00320801 | Jan 2004 → Mar 2005 | osteoarthritis | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00315458 | Dec 2003 → Mar 2005 | osteoarthritis | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00312572 | Jun 2003 → Jul 2004 | osteoarthritis | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00078117 | Jun 2003 → May 2005 | opiate dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT01141283 | Apr 2003 → Jul 2004 | osteoarthritis | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00313846 | Apr 2003 → Jun 2004 | osteoarthritis | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01151098 | Apr 2001 → Feb 2002 | chronic pain syndrome | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00312195 | Mar → Jul 2001 | chronic pain syndrome | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00032955 | Feb 2001 → Aug 2002 | heroin dependence, morphine dependence, substance withdrawal syndrome | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00032968 | Jan 2001 → Aug 2002 | heroin dependence, morphine dependence, substance withdrawal syndrome | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00313833 | Dec 2000 → Nov 2001 | chronic pain syndrome | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00314652 | Jun → Oct 1999 | osteoarthritis | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00315887 | Apr → Oct 1999 | chronic pain syndrome | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00315445 | Dec 1997 → May 1998 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00315874 | Apr 1997 → Jan 1998 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00315848 | Nov 1996 → Dec 1999 | osteoarthritis | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT00000311 | Feb 1995 → Feb 1999 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00000207 | May 1992 → Apr 1997 | substance-related disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00000205 | Oct 1990 → Mar 1993 | substance-related disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00000216 | ? → Jan 2005 | cocaine abuse, opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00000302 | — | heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 3 | NCT01713803 | ? → May 2017 | opiate dependence | BioDelivery Sciences International | Withdrawn | No outcome recorded |
| Phase 464 trials | ||||||
| Phase 4 | NCT07485335 | Sep 2026 → Sep 2030 expected | acute opioid poisoning, substance-related disorder | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07435077 | Aug → Dec 2026 expected | substance-related disorder | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06854029 | Jul 2026 → Dec 2029 expected | HIV infectious disease, opiate dependence | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07469501 | Jun 2026 → May 2027 expected | substance-related disorder | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07439549 | Apr → Sep 2026 expected | opiate dependence | Pouya Azar | Recruiting | No outcome recorded |
| Phase 4 | NCT07176351 | Apr 2026 → Feb 2027 expected | substance-related disorder | Yale University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07434427 | Feb 2026 → May 2027 expected | chronic pain syndrome | Medical University of Silesia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06949826 | Apr 2025 → Mar 2027 expected | opiate dependence | Jenna-Leigh Wilson | Recruiting | No outcome recorded |
| Phase 4 | NCT06367387 | May 2024 → Feb 2026 overdue | chronic pain syndrome, substance-related disorder | Erin Winstanley | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06133114 | Mar 2024 → Oct 2026 expected | — | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 4 | NCT05481112 | Nov 2023 → Nov 2025 | opiate dependence | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT05988710 | Oct 2023 → Jan 2028 expected | opioid abuse, pain agnosia | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05704543 | Mar → Nov 2023 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05824832 | Feb 2023 → Jun 2026 overdue | neuropathy, painful | Loyola University | Recruiting | No outcome recorded |
| Phase 4 | NCT05910190 | Aug 2022 → Oct 2024 | — | Fox Chase Cancer Center | Unknown | No outcome recorded |
| Phase 4 | NCT04981678 | Jan 2022 → Sep 2023 | opiate dependence | MaineHealth | Terminated | No outcome recorded |
| Phase 4 | NCT05042648 | Dec 2021 → Dec 2023 | — | Security Forces Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04995029 | Oct 2021 → Jun 2024 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04811014 | Apr 2021 → Aug 2030 expected | acute opioid poisoning, opiate dependence | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT04219540 | Jan 2021 → Aug 2024 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04375033 | Nov 2020 → Sep 2028 expected | opiate dependence | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT04283500 | Nov 2020 → Feb 2023 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04276259 | Oct 2020 → Jan 2026 | major depressive disorder | Marta Peciña, MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT04254081 | May 2020 → May 2021 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT04088266 | Jan → Dec 2020 | — | Teva Pharmaceuticals USA | Withdrawn | No outcome recorded |
| Phase 4 | NCT04060654 | Oct 2019 → May 2020 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03993392 | Aug → Dec 2019 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03908437 | Jul 2019 → Mar 2022 | opiate dependence, poisoning | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT03396276 | Apr 2018 → Aug 2030 expected | substance-related disorder | The University of Texas Health Science Center, Houston | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03033732 | Oct 2017 → Mar 2020 | substance-related disorder | Didier Jutras Aswad | Completed | No outcome recorded |
| Phase 4 | NCT02416804 | Jan 2015 → Jul 2016 | spinal stenosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02138357 | Apr 2014 → Dec 2016 | restless legs syndrome | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03117140 | Dec 2013 → Mar 2017 | — | Melinda Seering | Completed | No outcome recorded |
| Phase 4 | NCT01875848 | Dec 2013 → Jun 2015 | — | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 4 | NCT02038790 | Nov 2013 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01983111 | Oct 2013 → Nov 2014 | — | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02519387 | Jul 2013 → Jan 2015 | osteoarthritis, rheumatoid arthritis | Mundipharma Pharmaceuticals Sdn. Bhd. | Completed | No outcome recorded |
| Phase 4 | NCT01961271 | Jun 2013 → Jan 2015 | myopathy, osteoarthritis, rheumatoid arthritis | Mundipharma Pte Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03174067 | Mar 2013 → Apr 2016 | opiate dependence, substance withdrawal syndrome | St. Joseph's Health Centre Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01733693 | Jan 2013 → Jun 2017 | HIV infectious disease, opiate dependence | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01818700 | Sep 2012 → Jun 2013 | spinal cord disorder | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01846455 | Sep 2012 → Apr 2013 | chronic hepatitis C virus infection, liver failure | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02575664 | Aug 2012 → Oct 2015 | osteoarthritis | Kuopio University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01559454 | Feb 2012 → May 2014 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT01809106 | Apr 2011 → Oct 2014 | cancer | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT01546701 | Mar 2011 → Apr 2012 | urinary tract obstruction | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01276431 | Mar 2011 → Aug 2012 | osteoarthritis | Mundipharma Oy | Completed | No outcome recorded |
| Phase 4 | NCT00949299 | Jan 2010 → Dec 2011 | — | University of Zurich | Terminated | No outcome recorded |
| Phase 4 | NCT00964808 | Sep 2009 → May 2013 | neuropathy, painful | Vejle Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00955162 | Aug 2009 → May 2010 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00879996 | Apr 2009 → Oct 2011 | opiate dependence | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT00901875 | Mar → Nov 2009 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00750217 | Aug 2008 → Feb 2009 | heroin dependence | Psychiatric University Hospital, Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT00763958 | May 2008 → Sep 2009 | HIV infectious disease, opiate dependence | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT01019265 | Mar 2008 → Mar 2009 | osteoarthritis | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00604188 | Feb 2008 → Dec 2009 | opiate dependence | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00426647 | Feb 2007 → Jul 2009 | osteoarthritis | Norpharma A/S | Completed | No outcome recorded |
| Phase 4 | NCT00315341 | Apr 2006 → Aug 2010 | opiate dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00324038 | Mar 2006 → Dec 2007 | osteoarthritis | Napp Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 4 | NCT00310934 | Aug 2005 → Mar 2006 | heroin dependence | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00124358 | Aug 2005 → Dec 2008 | AIDS, opiate dependence | The New York Academy of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT00279565 | Aug 2005 → Feb 2007 | chronic hepatitis C virus infection | Indivior Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00367874 | Feb → Nov 2003 | opiate dependence, substance withdrawal syndrome | Sorlandet Hospital HF | Completed | No outcome recorded |
| Phase 4 | NCT00007527 | Aug 1999 → Jan 2002 | opiate dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT06772324 | Jan 2025 → Aug 2026 overdue | autism spectrum disorder | Peking University Sixth Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05871424 | Jun 2023 → Feb 2024 | gallbladder disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT05108935 | Feb 2022 → Mar 2023 | HIV infectious disease, hepatitis C virus infection, opiate dependence | Duke University | Completed | No outcome recorded |
| — | NCT05003765 | Aug 2020 → May 2022 | — | Wayne State University | Unknown | No outcome recorded |
| — | NCT03098407 | Apr 2017 → Oct 2019 | opiate dependence, pregnancy disorder | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT02737826 | May 2016 → Dec 2019 | chronic pain syndrome | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01583179 | Apr 2012 → Mar 2014 | — | University of Wisconsin, Madison | Terminated | No outcome recorded |
| — | NCT01648270 | Apr 2012 → Dec 2016 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01296334 | Feb → Sep 2011 | — | mads u werner | Completed | No outcome recorded |
| — | NCT01277159 | Oct 2010 → Dec 2011 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT01576575 | Jun 2010 → Mar 2014 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00913770 | Sep 2008 → Aug 2013 | opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT00679458 | Sep 2008 → Nov 2009 | — | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT00571961 | Jan 2007 → Aug 2008 | HIV infectious disease | Yale University | Completed | No outcome recorded |
| — | NCT00486330 | May 2006 → May 2007 | HIV infectious disease | Yale University | Completed | No outcome recorded |
| — | NCT00000243 | Sep 2002 → Jan 2004 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| — | NCT00134875 | Dec 2000 → Dec 2002 | substance-related disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| — | NCT00134888 | Dec 2000 → Nov 2002 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00158236 | Jan 1997 → Mar 1998 | opioid abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00134914 | Aug 1996 → Apr 1998 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 96 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05852093 Comparator | Jun 2023 → Jun 2026 overdue | rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT07169409 Background | Jun 2025 → Aug 2027 expected | substance-related disorder | Boulder Care | Recruiting | No outcome recorded |
| Phase 1 | NCT06406400 Background | May → Jul 2024 | opiate dependence | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04976855 Background | Aug 2022 → Jul 2023 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04447287 Background | Jun → Nov 2020 | substance-related disorder | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03268278 Comparator | Apr 2017 → Jul 2018 | — | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02559973 Background | Sep 2015 → Feb 2016 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02413281 Comparator | Mar → Sep 2015 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02045693 Comparator | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01723527 Background | Dec 2012 → May 2014 | HIV infectious disease, cocaine abuse, heroin dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01560221 Background | Oct 2012 → Dec 2014 | substance-related disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01377610 Comparator | Jun 2011 → Dec 2017 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT01046539 Comparator | Jan → Mar 2010 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00726960 Comparator | Jan 2008 → Dec 2009 | heroin dependence, opioid abuse | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01157169 Comparator | Aug → Sep 2007 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04818086 Comparator | May 2021 → Apr 2023 | substance-related disorder | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT01188421 Comparator | Oct 2010 → Jun 2015 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00000320 Comparator | Oct 1997 → Aug 1999 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07420283 Background | Feb 2026 → Mar 2028 expected | substance-related disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06576843 Background | Sep 2024 → Jan 2026 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04850664 Background | Mar 2021 → Nov 2022 | opiate dependence, substance withdrawal syndrome | Evon Medics LLC | Unknown | No outcome recorded |
| Phase 2 | NCT04677114 Background | Mar 2021 → Mar 2025 | opiate dependence, substance abuse | Laura Fanucchi | Completed | No outcome recorded |
| Phase 2 | NCT04225598 Comparator | Jul 2020 → Dec 2024 | opiate dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT03852628 Comparator | May 2019 → May 2022 | alcohol abuse, post-traumatic stress disorder | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Terminated | No outcome recorded |
| Phase 2 | NCT03150173 Background | Jan 2019 → Oct 2023 | opiate dependence | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03605342 Comparator | Oct 2018 → Apr 2023 | opiate dependence, post-traumatic stress disorder | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 2 | NCT03026790 Comparator | Oct 2017 → Mar 2022 | chronic pain syndrome | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01738503 Background | Oct 2012 → May 2014 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01262092 Comparator | Oct 2010 → Dec 2011 | opiate dependence, substance withdrawal syndrome | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT00000299 Background | Oct 2008 → Nov 2009 | substance-related disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00023283 Background | Aug 2000 → Dec 2003 | heroin dependence, substance abuse | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00000238 Background | Aug 1997 → ? | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000229 Background | Oct 1995 → ? | substance-related disorder | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00000228 Background | Aug 1994 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT04345718 Comparator | Aug 2021 → Aug 2025 | opiate dependence | Gavin Bart | Completed | No outcome recorded |
| Phase 2/3 | NCT04893525 Comparator | Jul 2021 → Dec 2026 expected | substance-related disorder | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03380533 Comparator | Sep 2016 → Dec 2017 | rotator cuff syndrome | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 2/3 | NCT02543944 Comparator | Feb 2016 → May 2021 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 2/3 | NCT02617199 Comparator | Nov 2015 → Dec 2016 | acute pancreatitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 2/3 | NCT01021696 Comparator | Nov 2009 → Jul 2010 | dementia | University of Bergen | Completed | No outcome recorded |
| Phase 2/3 | NCT00684554 Comparator | Dec 2007 → Aug 2008 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2027 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06023459 Comparator | Oct 2024 → Nov 2025 | substance-related disorder | Yih-Ing Hser | Completed | No outcome recorded |
| Phase 3 | NCT04116528 Comparator | Aug 2020 → Apr 2025 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT03918850 Comparator | Jul 2020 → Jan 2025 | drug dependence, neonatal abstinence syndrome, pregnancy disorder, substance abuse +1 | T. John Winhusen, PhD | Completed | No outcome recorded |
| Phase 3 | NCT02526212 Background | Jan 2017 → May 2019 | opioid abuse | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02696434 Background | Apr 2016 → Nov 2017 | substance-related disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02510014 Background | Jul 2015 → Jan 2017 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02357901 Background | Jan 2015 → Apr 2016 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02180659 Comparator | Jul 2014 → May 2015 | opiate dependence | Titan Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01908842 Comparator | Aug 2013 → Apr 2014 | opiate dependence | Orexo AB | Completed | No outcome recorded |
| Phase 3 | NCT01848054 Comparator | Jun 2013 → Jan 2014 | opiate dependence | Orexo AB | Completed | No outcome recorded |
| Phase 3 | NCT01717963 Comparator | Oct 2012 → Aug 2016 | opiate dependence | University of Oslo | Completed | No outcome recorded |
| Phase 3 | NCT01131273 Comparator | Jun 2010 → Aug 2013 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT01476774 Comparator | Aug 2009 → Jun 2010 | intervertebral disk degenerative disorder | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01046851 Comparator | Sep 2008 → Dec 2011 | — | Prof. Yoram Yovell | Unknown | No outcome recorded |
| Phase 3 | NCT00647127 Comparator | Feb 2008 → Aug 2009 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00863291 Comparator | Nov 2007 → Nov 2008 | depressive disorder | Abarbanel Mental Health Center | Unknown | No outcome recorded |
| Phase 3 | NCT00447564 Comparator | Oct 2006 → Jul 2008 | opiate dependence | Titan Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02516436 Comparator | ? → May 2017 | opiate dependence | BioDelivery Sciences International | Withdrawn | No outcome recorded |
| Phase 426 trials | ||||||
| Phase 4 | NCT07097493 Comparator | Aug → Dec 2026 expected | osteoarthritis, knee | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06880718 Comparator | Feb 2026 → Jan 2027 expected | opiate dependence | Lifespan | Recruiting | No outcome recorded |
| Phase 4 | NCT06051890 Comparator | Jun 2025 → Dec 2026 expected | opiate dependence | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 4 | NCT06742554 Comparator | Dec 2024 → Apr 2025 overdue | — | medina medical center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05450718 Comparator | Nov 2024 → Mar 2027 expected | substance-related disorder | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06323824 Comparator | Jun 2024 → Dec 2028 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
| Phase 4 | NCT05594121 Comparator | Dec 2022 → Dec 2023 | opiate dependence | Royal Victoria Hospital, Canada | Unknown | No outcome recorded |
| Phase 4 | NCT05118204 Comparator | Sep 2022 → Oct 2024 | chronic pain syndrome, opiate dependence | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT05419297 Comparator | Aug 2022 → Jul 2023 | chronic pain syndrome | Carolinas Pain Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04771689 Comparator | Jul 2022 → Dec 2025 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03845894 Comparator | Mar 2020 → Jun 2022 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT04212065 Comparator | Feb → Sep 2020 | substance-related disorder | Ohio State University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04234516 Comparator | Jan 2020 → Jun 2021 | opiate dependence | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT04464512 Comparator | Jan 2020 → Aug 2021 | chronic pain syndrome, disease of bone structure, opiate dependence | West Virginia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03604159 Comparator | Jun 2019 → May 2020 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03740243 Comparator | Nov 2018 → Mar 2020 | substance-related disorder | Stony Brook University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02267057 Comparator | Aug 2014 → Dec 2016 | dementia, depressive disorder | University of Bergen | Completed | No outcome recorded |
| Phase 4 | NCT02162121 Background | May 2014 → Oct 2016 | — | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 4 | NCT02032433 Comparator | Jan 2014 → Jan 2017 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT01843023 Comparator | Jun 2013 → Jan 2018 | drug dependence | Friends Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01854489 Comparator | Apr 2013 → Nov 2014 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01298297 Comparator | Feb 2010 → Mar 2011 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01015066 Comparator | Nov 2009 → Jun 2014 | opiate dependence | State University of New York at Buffalo | Withdrawn | No outcome recorded |
| Phase 4 | NCT00916890 Comparator | Feb 2009 → Feb 2015 | chronic pain syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Suspended | No outcome recorded |
| Phase 4 | NCT00605033 Comparator | Mar 2008 → Apr 2009 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00684073 Background | Jul → Dec 2007 | opiate dependence, substance abuse | Indivior Inc. | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT05270434 Background | Mar → Oct 2025 | chronic pancreatitis | Changhai Hospital | Completed | No outcome recorded |
| — | NCT05091138 Comparator | Oct 2021 → Oct 2022 | — | Wayne State University | Unknown | No outcome recorded |
| — | NCT05090761 Comparator | Oct 2021 → Oct 2022 | — | Wayne State University | Unknown | No outcome recorded |
| — | NCT03586466 Background | Dec 2018 → Sep 2020 | opiate dependence | MedicaSafe, Inc. | Unknown | No outcome recorded |
| — | NCT02971475 Background | Nov 2016 → May 2019 | chronic pancreatitis | Changhai Hospital | Unknown | No outcome recorded |
| — | NCT02659787 Comparator | Jun 2016 → Apr 2017 | depressive disorder | University of Chicago | Completed | No outcome recorded |
| — | NCT02136784 Comparator | Apr → Dec 2014 | — | University of California, Los Angeles | Unknown | No outcome recorded |
| — | NCT01550341 Comparator | Feb 2012 → Nov 2015 | AIDS, opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT00929253 Comparator | Sep 2007 → Apr 2010 | opiate dependence | Virginia Polytechnic Institute and State University | Completed | No outcome recorded |
| — | NCT00249574 Background | Jun 2003 → Mar 2004 | hepatitis C virus infection, heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 416 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buprenorphine | “In collaboration with the National Institute on Drug Abuse (NIDA), Alkermes, Inc. is investigating a fixed-dose combination product consisting of ALKS 33 (also referred to as...” NCT01366001 ↗382“Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and...” NCT04408313 ↗ “OBJECTIVE: To evaluate the ability of a novel, weekly, subcutaneous buprenorphine depot formulation, CAM2038, to block euphorigenic opioid effects and suppress opioid...” PMID 28655025 ↗ Sep 2017 “SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at...” NCT03818399 ↗ “SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at...” NCT04523792 ↗ “Sublocade and Brixadi, two distinct, branded, formulations of extended-release buprenorphine (XR-B), offer a promising approach to improving MOUD treatment adherence and...” PMID 40645369 ↗ Jul 2025 “The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy,...” NCT00000331 ↗ “CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections compared to daily sublingual (SL) BPN/naloxone (BPN/NX) tablets, and equivalent placebos, in OUD...” PMID 39629836 ↗ Dec 2024 “The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of...” NCT00733720 ↗ “A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment.” NCT02038790 ↗ “Buprenorphine is a partial μ-opioid receptor agonist that, unlike full μ-opioid receptor agonists, has been shown to have a ceiling effect on respiratory depression.” PMID 32978722 ↗ Sep 2020 “The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone combination tablet to methadone for opioid maintenance treatment.” NCT00000328 ↗ “After induction with sublingual buprenorphine-naloxone tablets, patients received either 4 buprenorphine implants (80 mg per implant) or 4 placebo implants.” PMID 20940383 ↗ Oct 2010 “Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain.” NCT06367387 ↗ “XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder” NCT04219540 ↗ “Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.” NCT01582347 ↗ “INTERVENTION: Injection of a 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038) and referral for ongoing OUD care.” PMID 38976265 ↗ Jul 2024 “Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.” NCT03770234 ↗ “new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV) and extended-release buprenorphine (XR-B)” NCT05991622 ↗ “Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.” NCT03845894 ↗ “INDV-6200 is a novel buprenorphine subcutaneous (SC) depot formulation being developed for the treatment of opioid dependency.” NCT03715634 ↗ “Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN).” NCT01262261 ↗ “The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg).” NCT03861338 ↗ “Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).” NCT04850664 ↗ “A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system” NCT02765867 ↗ “and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion” NCT02617199 ↗ “Buprenorphine (BNP) has gained widespread use in the treatment of adult opioid dependence.” NCT02249026 ↗ “Subcutaneous buprenorphine delivered weekly or monthly (CAM2038) was well tolerated” PMID 31013390 ↗ Jun 2019 “Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours” NCT05118204 ↗ “low-dose oral naltrexone (NTX), combined with a brief buprenorphine (BUP) taper” PMID 29674251 ↗ Apr 2018 “Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.” NCT01760473 ↗ “Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks)” NCT03852628 ↗ “Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily” NCT01755546 ↗ “Buprenorphine Transdermal Delivery System Second Generation Patches” NCT02160067 ↗ “Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion” NCT02431624 ↗ “2 mg/2 mg of buprenorphine/samidorphan (the 2/2 dosage group)” PMID 26869247 ↗ Feb 2016 “Samidorphan + buprenorphine, administered sublingually” NCT03188185 ↗ “samidorphan + buprenorphine administered sublingually” NCT03610048 ↗ “IV buprenorphine plus IV sufentanil treatment group.” NCT04464512 ↗ “Contains Buprenorphine Hydrochloride.” NCT00604188 ↗ “Buprenorphine/Naloxone 4/1 mg, 8/2 mg” NCT00710385 ↗ “8mg of buprenorphine/2mg of naloxone” NCT03396276 ↗ “sublingual buprenorphine/naloxone” NCT03744663 ↗ “Buprenorphine Buccal Films” NCT05427981 ↗ “Buprenorphine” NCT07296770 ↗ “buprenorphine” NCT04234516 ↗ “Buprenorphine” NCT07296770 ↗ |
| Known as | Belbuca | “Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours” NCT05118204 ↗1“Buprenorphine 0.15 MG [Belbuca]” NCT05778591 ↗ |
| Known as | BEMA Buprenorphine | “BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa.” NCT01431742 ↗1“BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa.” NCT01298765 ↗ |
| Known as | BNP | “Buprenorphine (BNP) has gained widespread use in the treatment of adult opioid dependence.” NCT02249026 ↗ |
| Known as | BPN | “The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized...” NCT02180659 ↗3“Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen,...” NCT00367874 ↗ “Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in...” NCT00630201 ↗ “AIMS: To provide controlled data on direct induction with buprenorphine/naloxone (BNX) versus indirect buprenorphine (BPN)-to-BNX induction.” PMID 21749526 ↗ Oct 2011 |
| Known as | BRIXADI | “This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release...” NCT07524738 ↗3“Sublocade and Brixadi, two distinct, branded, formulations of extended-release buprenorphine (XR-B), offer a promising approach to improving MOUD treatment adherence and...” PMID 40645369 ↗ Jul 2025 “This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail.” NCT06306443 ↗ |
| Known as | BSL | “sublingual buprenorphine (BSL)” NCT04352166 ↗ |
| Known as | BTDS | “The primary objective of this study is to evaluate the efficacy and safety of buprenorphine transdermal system (BTDS) compared to placebo in subjects with moderate to severe...” NCT00345787 ↗7“OBJECTIVES: The aim of this noninferiority study was to investigate clinical effectiveness and safety of buprenorphine transdermal system (BTDS) in patients with moderate to...” PMID 25503600 ↗ Jul 2015 “Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Mod to...” NCT01141283 ↗ “The objectives in this study are to evaluate: (1) efficacy of buprenorphine transdermal system (BTDS, Butrans™) on postoperative pain following total knee replacement surgery;” NCT00403234 ↗ “A Double-Blind Comparative Study of Buprenorphine Transdermal System (BTDS) and Hydrocodone/Acetaminophen Tablets in Patients With Chronic Back Pain” NCT00315887 ↗ “Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain” NCT00346047 ↗ “Buprenorphine transdermal (BTDs) is a semi-synthetic opioid analgesic.” NCT02519387 ↗ “buprenorphine transdermal delivery system (BTDS), brand name Butrans.” NCT02138357 ↗ |
| Known as | BUP | “HIV-seronegative subjects stabilized on at least 3 weeks of buprenorphine/naloxone (BUP/NLX) therapy sequentially underwent baseline and steady-state pharmacokinetic evaluation” PMID 19726139 ↗ Sep 200910“Buprenorphine (BUP) is a partial opiate agonist dosed sublingually for both supervised opiate withdrawal and maintenance for opiate dependence.” NCT00571961 ↗ “Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).” NCT04850664 ↗ “Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.” NCT02543944 ↗ “Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day” NCT06323824 ↗ “12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose” NCT05589181 ↗ “sublingual BUP (as Suboxone®) in the presence of extended-release injectable naltrexone” PMID 23159524 ↗ Nov 2012 “low-dose oral naltrexone (NTX), combined with a brief buprenorphine (BUP) taper” PMID 29674251 ↗ Apr 2018 “12-16 mg of transmucosal (TM) BUP (SUBOXONE®)” NCT06576843 ↗ “buprenorphine (BUP) discontinuation” NCT03232346 ↗ “Buprenorphine (BUP)” NCT02360007 ↗ |
| Known as | BUP-Inj | “Buprenorphine injection (BUP-Inj)” NCT05283304 ↗ |
| Known as | BUP-XR | “Buprenorphine extended-release monthly formulation (BUP-XR, SUBLOCADE®) is approved for treatment of moderate-to-severe opioid use disorder (OUD) following subcutaneous...” PMID 39543001 ↗ Nov 20241“Subcutaneously injected, extended-release buprenorphine (BUP-XR) may be more effective-but there has been no superiority evaluation.” PMID 38045803 ↗ Nov 2023 |
| Known as | Buprenex | “one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006)” NCT04276259 ↗1“Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks)” NCT03852628 ↗ |
| Known as | Buprenex (buprenorphine) | “Buprenex (buprenorphine)” NCT00521248 ↗ |
| Known as | Buprenorphine and naloxone sublingual film | “Buprenorphine and naloxone sublingual film” NCT02477267 ↗ |
| Known as | buprenorphine buccal film | “A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive.” PMID 32978722 ↗ Sep 2020 |
| Known as | buprenorphine HCl | “Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.” NCT00772785 ↗ |
| Known as | buprenorphine hydrochloride | “Participants were randomized to receive sublingual buprenorphine plus 4 placebo implants or sublingual placebo plus four 80-mg buprenorphine hydrochloride implants (expected...” PMID 27434441 ↗ Jul 20166“Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence.” NCT01560221 ↗ “BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa.” NCT01298765 ↗ “BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa.” NCT01431742 ↗ “one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006)” NCT04276259 ↗ “Subutex, Buprenorphine Hydrochloride, SCH 28444” NCT00605033 ↗ |
| Known as | Buprenorphine Transdermal System | “Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Mod to...” NCT01141283 ↗3“A Double-Blind Comparative Study of Buprenorphine Transdermal System (BTDS) and Hydrocodone/Acetaminophen Tablets in Patients With Chronic Back Pain” NCT00315887 ↗ “Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain” NCT00346047 ↗ “Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks” NCT00345787 ↗ |
| Known as | Buprenorphine transdermal system (BTDS) | “Buprenorphine transdermal system (BTDS)” NCT01019265 ↗ |
| Known as | Buprenorphine/Naloxone | “Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder.” NCT03033732 ↗9“Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours” NCT05118204 ↗ |
| Known as | Butrans | “hydrocodone/ acetaminophen (Vicodin®) to the buprenorphine transdermal system (Butrans™)” NCT00312572 ↗ |
| Known as | BXR | “The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg).” NCT03861338 ↗1“extended-release buprenorphine (BXR)” NCT04352166 ↗ |
| Known as | CAM2038 | “OBJECTIVE: To evaluate the ability of a novel, weekly, subcutaneous buprenorphine depot formulation, CAM2038, to block euphorigenic opioid effects and suppress opioid...” PMID 28655025 ↗ Sep 20175“CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections compared to daily sublingual (SL) BPN/naloxone (BPN/NX) tablets, and equivalent placebos, in OUD...” PMID 39629836 ↗ Dec 2024 “Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.” PMID 31013390 ↗ Jun 2019 “The XR-BUP condition will use Brixadi®/CAM2038 injectable, extended-release buprenorphine.” NCT06023459 ↗ |
| Known as | Extended-release Buprenorphine | “This is a clinical trial to characterize the safety and pharmacokinetics of using extended-release buprenorphine (XR-BUP) as a novel low-dose buprenorphine induction strategy.” NCT06441604 ↗1“Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen.” NCT05262270 ↗ |
| Known as | extended-release buprenorphine (XR-B) "sublocade" | “extended-release buprenorphine (XR-B) "sublocade"” NCT05991622 ↗ |
| Known as | INDV-6200 | “INDV-6200 is a novel buprenorphine subcutaneous (SC) depot formulation being developed for the treatment of opioid dependency.” NCT03715634 ↗ |
| Known as | Nopan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01046851 ↗ |
| Known as | Norspan | “A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of NORSPAN® (Buprenorphine) in Korean Patients With Spinal Disorders (NOBLE)” NCT01818700 ↗1“NORSPAN Buprenorphine Transdermal Patchs for Lower dose group” NCT06772324 ↗ |
| Known as | Other Name: Buprenex (buprenorphine) | “Other Name: Buprenex (buprenorphine)” NCT01708707 ↗ |
| Known as | Probuphine | “Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in...” NCT00447564 ↗5“Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN).” NCT01114308 ↗ “Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN.” NCT00772785 ↗ “Probuphine (buprenorphine implant)” NCT00630201 ↗ “Probuphine (buprenorphine implant)” NCT00768482 ↗ |
| Known as | SCH 28444 | “Subutex, Buprenorphine Hydrochloride, SCH 28444” NCT00605033 ↗ |
| Known as | SL-B | “This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release...” NCT07524738 ↗1“Sublingual Buprenorphine (SLB)” NCT06051890 ↗ |
| Known as | Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03604159 ↗ |
| Known as | Sublocade | “SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at...” NCT04523792 ↗8“SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at...” NCT03818399 ↗ “Sublocade and Brixadi, two distinct, branded, formulations of extended-release buprenorphine (XR-B), offer a promising approach to improving MOUD treatment adherence and...” PMID 40645369 ↗ Jul 2025 “The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg).” NCT03861338 ↗ “Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade)” NCT06323824 ↗ |
| Known as | Suboxone | “buprenorphine-naloxone (Suboxone) for 12 weeks” NCT01131273 ↗ |
| Known as | Subutex | “Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence.” NCT01560221 ↗4“This study seeks to improve the treatment of chronic pain in people who are taking buprenorphine (also known as Suboxone, Subutex, Zubsolv).” NCT06367387 ↗ “Subutex, Buprenorphine Hydrochloride, SCH 28444” NCT00605033 ↗ “Buprenorphine/Subutex” NCT00383045 ↗ |
| Known as | Subutex (buprenorphine sublingual tablets) | “Subutex (buprenorphine sublingual tablets)” NCT00750217 ↗ |
| Known as | T2rev | “new buprenorphine transdermal patch T2rev formulation containing 13 mg buprenorphine (Test) as compared to Transtec(R) PRO 70 µg/h patch transdermal patch containing 40 mg...” NCT00387777 ↗ |
| Known as | Temgesic | “Investigators will administer placebo, 0.2 mg buprenorphine (Temgesic) via sublingual tablet in counterbalanced order under double-blind conditions.” NCT02659787 ↗ |
| Known as | Transtec | “Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.” NCT03785613 ↗1“application of the Transtec (Registered Trademark) patch” NCT03770234 ↗ |
| Known as | Transtec (buprenorphine patch) | “Transtec (buprenorphine patch)” NCT00750217 ↗ |
| Known as | Transtec (R) PRO | “Transtec (R) PRO (buprenorphine)” NCT00388219 ↗ |
| Known as | XR-BUP | “This protocol describes an open-label randomized comparative effectiveness trial comparing ACS treatment as usual (TAU) to a single injection of a 28-day formulation...” PMID 39623502 ↗ Dec 20242“The study is a single-blind, fixed-order, dose-escalation designed trial in an inpatient setting with individuals with a DSM-5 diagnosis of OUD (n=30). The first 10...” NCT06441604 ↗ |
| Known as | XR-BUP (Brixadi) | “XR-BUP (Brixadi)” NCT06023459 ↗ |
| Known as | XRB | “County jails willing to provide extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-B) will participate in a randomized controlled trial throughout the...” NCT04408313 ↗4“This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail.” NCT06306443 ↗ “Participants will initiate extended-release buprenorphine (XR-B) treatment at the time of admission.” NCT05481112 ↗ “Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment” PMID 35093164 ↗ Jan 2022 “Extended-Release Buprenorphine (XRB)” NCT06051890 ↗ |
| Known as | Zubsolv | “Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)” NCT07469501 ↗ |
| Action | Activate | “Buprenorphine, a partial mu-opioid agonist, is an alternative treatment for opioid dependence but has not been extensively studied in pregnancy.” PMID 21142534 ↗ Dec 2010 |
| Modality | Other / unclassified | “mixed opioid agonist-antagonist buprenorphine” NCT00863291 ↗ |
| Route | Intravenous | “intravenous buprenorphine” NCT00000331 ↗ |